Healthy Business Matters: GLP-1's Alone Are Not a Metabolic Strategy

Episode notes

GLP-1s are powerful. They reduce appetite. They lower A1C. They drive meaningful weight loss. For many patients, they are clinically appropriate and life-changing. What’s controversial isn’t the drug. It’s how employers are deploying it. In too many health plans, GLP-1s are being used as the metabolic strategy instead of as a tool inside one. And those are not the same thing. In this episode, Dr. Andrew White breaks down why weight loss alone does not equal metabolic durability and why employers who ignore sequencing, movement capacity, and off-ramps may be increasing long-term pharmacy exposure instead of reducing risk. If you’re a CFO, broker, HR leader, or operator evaluating GLP-1 coverage, this episode gives you a practical framework you can use in your next renewal meeting.

• How Employers Can Get Better Healthcare for Less: Breaking the Status Quo with Dan Cosgrove66 / 100
• Healthy Business Podcast: Movement Capacity Is the Missing Variable in Your Metabolic Strategy87 / 100
• Healthy Business Matters: MSK Is The Trojan Horse For Metabolic Risk
• Healthy Business Matters: Where Care Starts is Where Costs Are Decided
• Healthy Business Matters : Why so many 'Proactive' Health Programs Stay Reactive